Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation

Kim, Sang Jin; Rhu, Jinsoo; Yoo, Heejin; Kim, Kyunga; Lee, Kyo Won; Park, Jae Berm

doi:10.3390/jcm9051320

Open AccessArticle

Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation

by

Sang Jin Kim

¹

,

Jinsoo Rhu

¹,

Heejin Yoo

²,

Kyunga Kim

²,

Kyo Won Lee

^1,* and

Jae Berm Park

^1,*

¹

Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea

²

Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06355, Korea

^*

Authors to whom correspondence should be addressed.

J. Clin. Med. 2020, 9(5), 1320; https://doi.org/10.3390/jcm9051320

Submission received: 14 April 2020 / Revised: 28 April 2020 / Accepted: 29 April 2020 / Published: 2 May 2020

(This article belongs to the Special Issue Clinical Complications after Kidney Transplantation)

Download

Browse Figures

Review Reports Versions Notes

Abstract

The objective of this study was to compare outcomes between basiliximab and low-dose r-ATG in living donor kidney transplantation recipients with low immunological risk. Patients in the low-dose r-ATG group received 1.5 mg/kg of r-ATG for 3 days (total 4.5 mg/kg). Graft survival, patient survival, acute rejection, de novo donor specific antibody (DSA), estimated glomerular filtration rate (e-GFR) changes, and infection status were compared. Among 268 patients, 37 received r-ATG, and 231 received basiliximab. There was no noticeable difference in the graft failure rate (r-ATG vs. basiliximab: 2.7% vs. 4.8%) or rejection (51.4% vs. 45.9%). de novo DSA was more frequent in the r-ATG group (11.4% vs. 2.4%, p = 0.017). e-GFR changes did not differ noticeably between groups. Although most infections showed no noticeable differences between groups, more patients in the r-ATG group had cytomegalovirus (CMV) antigenemia and serum polyomavirus (BK virus) (73.0% vs. 51.9%, p = 0.032 in CMV; 37.8% vs. 15.6%, p = 0.002 in BK), which did not aggravate graft failure. Living donor kidney transplantation patients who received low-dose r-ATG and patients who received basiliximab showed comparable outcomes in terms of graft survival, function, and overall infections. Although CMV antigenemia, BK viremia were more frequent in the r-ATG group, those factors didn’t change the graft outcomes.

Keywords: basiliximab; rabbit anti-thymocyte globulin; graft survival; kidney transplantation

Share and Cite

MDPI and ACS Style

Kim, S.J.; Rhu, J.; Yoo, H.; Kim, K.; Lee, K.W.; Park, J.B. Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation. J. Clin. Med. 2020, 9, 1320. https://doi.org/10.3390/jcm9051320

AMA Style

Kim SJ, Rhu J, Yoo H, Kim K, Lee KW, Park JB. Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation. Journal of Clinical Medicine. 2020; 9(5):1320. https://doi.org/10.3390/jcm9051320

Chicago/Turabian Style

Kim, Sang Jin, Jinsoo Rhu, Heejin Yoo, Kyunga Kim, Kyo Won Lee, and Jae Berm Park. 2020. "Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation" Journal of Clinical Medicine 9, no. 5: 1320. https://doi.org/10.3390/jcm9051320

APA Style

Kim, S. J., Rhu, J., Yoo, H., Kim, K., Lee, K. W., & Park, J. B. (2020). Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation. Journal of Clinical Medicine, 9(5), 1320. https://doi.org/10.3390/jcm9051320

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI